CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial

Guideline24 February 2021

JOURNAL:National Institue for Health and Care Excellence Article Link

Dapagliflozin for treating chronic heart failure with reduced ejection fraction

National Institue for Health and Care Excellence Keywords: HFrEF; guideline; NICE

Full Text PDF